{
    "Question": " Should patients with RA who have not been previously treated with boDMARD and tsDAMRD receive T2T strategies or usual care?",
    "Comparison": 
    {
        "T2T strategy versus usual care": 
        {   "filename": "PICO 12a_Comparison 1.json",
                "Explanations": 
                {
            "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and lack of blinding.",
            "b": "Downgraded by one level due to serious imprecision. Small sample size.",
            "c": "Downgraded by two levels due to very serious inconsistency. I2= 96%.",
            "d": "Downgraded by two levels due to very serious risk of bias. Lack of allocation concealment, lack of blinding, and attrition bias.",
            "e": "Downgraded by one level due to serious inconsistency. I2= 78%.",
            "f": "Downgraded by one level due to serious inconsistency. I2= 71%.",
            "g": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect.",
            "h": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting no effect. Small sample size.",
            "i": "Downgraded by one level due to serious inconsistency. I2= 74%.",
            "j": "Downgraded by one level due to serious inconsistency. I2= 75%.",
            "k": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events.",
            "l": "Downgraded by two levels due to very serious risk of bias. Two studies consisting of 97% of the weight have high risk of bias due to lack of allocation concealment, lack of blinding of outcome assessors, and reporting incomplete outcome data.",
            "m": "I2=55%",
            "n": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Low number of events.",
            "o": "Downgraded by one level due to serious risk of bias. Lack of blinding.",
            "p": "Downgraded by two levels due to very serious imprecision. Very small number of events."
        }   
    }
    },
    "References": 
    {
        "1": "Mueller RBea. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine. 2019;8.",
        "2": "Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263.",
        "3": "Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis care & research. 2013;65(9):1401.",
        "4": "Verstappen SM, Jacobs JW, Veen MJVD, Heurkens AH, Schenk Y, Borg EJt, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the Rheumatic Diseases. 2007;66(11):1443.",
        "5": "Fransen J. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis BMJ. 2005; 64:1294â€“1298.",
        "6": "Verstappen SMB, M. F.; et. al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis BMJ. 2010;69(6):1044-8.",
        "7": "Wailoo A. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. [Review]. Health Technology Assessment (Winchester, England). 2017;21(71):1."
    }
}